Shuttle Pharmaceuticals (NASDAQ:SHPH) has announced the successful dosing of the first three patients in its Phase 2 clinical trial of Ropidoxuridine, aimed at treating glioblastoma.
Ropidoxuridine, Shuttle’s lead candidate radiation sensitizer, is designed to enhance the effectiveness of radiotherapy in combating glioblastoma, a highly aggressive and incurable brain malignancy. Shuttle has also received Orphan Drug Designation from the FDA, offering potential marketing exclusivity upon the therapy’s initial FDA approval for this condition.
“The initiation of patient dosing in our Phase 2 trial of Ropidoxuridine for the treatment of patients with glioblastoma is a significant milestone for both Shuttle Pharma and the thousands of patients with brain tumors who currently lack effective therapies,” commented Shuttle Pharma’s chairman and CEO, Anatoly Dritschilo, M.D. “The results of this trial will be important as Shuttle Pharma looks to leverage radiation sensitizers to increase cancer cure rates, prolong patient survival, and improve quality of life for patients suffering from glioblastoma.”
